IMU (ASX) Ann: Imugene PD1-Vaxx patent extended to 2040

Originally posted by Jase99: ↑

I don't usually lookup patents, but I was really intrigued as to how they were able to extend it and I think I've found the reason; which may also explain why there is yet to be a deal for HER-Vaxx and one of the reasons for the HER-Vaxx combo trial with Pembrolizumab.

Here's a link to a copy of the patent: WO2018183488 HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF (wipo.int)

Whilst I haven't checked this against the original patent, I found these parts extremely interesting:

15. The pharmaceutical composition of claim 14, further comprising one or more HER-2 B cell epitopes.
16. The pharmaceutical composition of claim 15, wherein the HER-2 B cell epitopes comprises one or more of the sequences as set forth in SEQ ID NO: 27 or 29.
17. The pharmaceutical composition of claim IS, wherein the HER-2 B cell epitopes comprises one or more synthetic HER-2 B cell epitopes as set forth in SEQ ID NO: 28 or 30.
23. The method of any of claims 20-22, wherein the cancer is selected from the group of cancers consisting of lymphoma, B cell lymphoma, T cell lymphoma, mycosis fungoides, Hodgkin's Disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, squamous cell carcinoma of head and neck, lung cancer, small cell lung carcinoma, non-small cell lung carcinoma, neuroblastoma, glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, squamous cell carcinomas of the mouth, throat, larynx, and lung, colon cancer, cervical cancer, cervical carcinoma, breast cancer, epithelial cancer, renal cancer, genitourinary cancer, pulmonary cancer, esophageal carcinoma, head and neck carcinoma, large bowel cancer, hematopoietic cancer; testicular cancer; prostatic cancer, or pancreatic cancer.
24. The method of claim 23, wherein the cancer is breast cancer.
25. The method of claim 24, wherein the method further comprises administering to the subject one or more one or more HER-2 B cell epitopes.
26. The method of claim 25, wherein the HER-2 B cell epitopes comprises one or more of the sequences as set forth in SEQ ID NO: 27 or 29.
27. The method of claim 25, wherein the HER-2 B cell epitopes comprises one or more synthetic HER-2 B cell epitopes as set forth in SEQ ID NO: 28 or 30.
28. The method of claim 25, wherein the HER-2 B cell epitopes are administered in the same composition with the PD-1 epitopes.

Have a look at all the cancers they are expecting to target with PD1-Vaxx.
It appears IMU is planning to do a PD1-Vaxx - HER-Vaxx combination and may well be the reason for holding off on licencing HER-Vaxx as a standalone product.

I also found this part very interesting:

20. A method of treating a cancer, Alzheimer's disease, or autoimmune disease in a subject comprising administering to the subject any of the peptides or compositions of any of claims 1- 19.
21. A method of treating a cancer, Alzheimer' s disease, or an autoimmune disease in a subject comprising administering to a subject a PD-1 chimeric peptide wherein the chimeric peptide comprises one or more PD-1 B cell epitopes, a T helper (Th) epitope, and a linker joining the PD-1 B cell epitope to the Th epitope, wherein the one or more PD-1 B cell epitopes consist of a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.
22. A method of treating a cancer, Alzheimer's disease, or autoimmune disease in a subject comprising administering to a subject a PD-1 synthetic peptide wherein the PD-1 synthetic peptide comprises one or more of the sequences as set forth in SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15.
29. The method of any of claims 20-22, wherein the autoimmune disease is selected from the group consisting of Psoriasis, Alopecia Areata, Primary biliary cirrhosis, Autoimmune polyendocrine syndrome, Diabetes mellitus type 1, autoimmune thyroiditis, Systemic Lupus Erythematosus, Multiple sclerosis, Guillain-Barre syndrome, Grave's disease, Sjogren's syndrome, ulcerative colitis, Autoimmune hemolytic anemia, Pernicious anemia, Psoriatic arthritis, rheumatoid arthritis, relapsing polychondritis, myasthenia gravis, Acute disseminated encephalomyelitis, and Granulomatosis with polyangiitis.

I wasn't aware PD1 targeting drugs could be used for other diseases, but it seems there must research to suggest it may be helpful, otherwise why bother including it in the patent?

Expand

That is actually pretty interesting as like yourself I thought it was just cancer it was looking to treat.
it may well be nothing and has just grouped them together for whatever reason.
There's me thinking "meh, just extending a patent by a couple of years. No biggy really"

No.	Vol.	Price($)
6	1468251	5.3¢

No.

Vol.

Price($)

1468251

5.3¢

Price($)	Vol.	No.
5.4¢	457393	5

Price($)

Vol.

No.

5.4¢

457393

No.	Vol.	Price($)
6	1468251	0.053
14	1956862	0.052
30	3768447	0.051
78	7419000	0.050
25	3385007	0.049

No.

Vol.

Price($)

1468251

0.053

1956862

0.052

3768447

0.051

7419000

0.050

3385007

0.049

Price($)	Vol.	No.
0.054	457393	5
0.055	878148	7
0.056	920184	8
0.057	1624353	11
0.058	1120000	6

Price($)

Vol.

No.

0.054

457393

0.055

878148

0.056

920184

0.057

1624353

0.058

1120000

(20min delay)
Last 5.3¢		Change 0.000(0.00%)		Mkt cap ! $389.5M

Open	High	Low	Value	Volume
5.3¢	5.4¢	5.1¢	$717.6K	13.61M

Ann: Imugene PD1-Vaxx patent extended to 2040, page-21

Trimmed CPI figure provokes market jump of 1%, but inflation pressures remain a reality

New results confirm Buena Vista's iron grades potential

Koba, formerly a cobalt player, gears up to become newest explorer in the uranium state: South Australia

One Click Group jumps 4% after ending quarter with $2.4M in cash; $1M in revenue and 150K+ users on board

Mineral Commodities to shut down Tormin mineral sands project as oil spill contaminates beach

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Imugene PD1-Vaxx patent extended to 2040, page-21

Top Stories

Trimmed CPI figure provokes market jump of 1%, but inflation pressures remain a reality

New results confirm Buena Vista's iron grades potential

Koba, formerly a cobalt player, gears up to become newest explorer in the uranium state: South Australia

One Click Group jumps 4% after ending quarter with $2.4M in cash; $1M in revenue and 150K+ users on board

Mineral Commodities to shut down Tormin mineral sands project as oil spill contaminates beach

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News